Corona Remedies IPO Listing: GMP Hits 32% Ahead of Debut

Strong Investor Interest Ahead of Listing

Corona Remedies, a prominent pharmaceutical company, is scheduled to make its stock market debut on December 15, 2025. The company's Initial Public Offering (IPO) has generated significant buzz among investors, reflected in a strong Grey Market Premium (GMP) that has climbed to 32%. This positive sentiment suggests market participants anticipate a robust listing for the stock. The allotment of shares was finalized on December 11, 2025, setting the stage for the final listing process.

Overwhelming Subscription Response

The IPO, which was open for bidding from December 8 to December 10, 2025, received an overwhelming response from all categories of investors. According to data from the stock exchange, the public issue was oversubscribed by a remarkable 137.04 times. The demand was particularly strong from Qualified Institutional Buyers (QIBs), whose portion was subscribed 278.52 times. Non-Institutional Investors (NIIs) also showed keen interest, oversubscribing their allocated portion by 208.88 times. Retail investors subscribed 28.73 times, indicating broad-based participation in the offering.

IPO Structure and Financials

The Corona Remedies IPO was entirely an Offer for Sale (OFS), through which existing shareholders sold 0.62 crore shares to raise ₹655.37 crore. The company itself will not receive any proceeds from the issue. The price band for the IPO was fixed at ₹1,008 to ₹1,062 per equity share, with a face value of ₹10. The lot size for retail investors was set at 14 shares, translating to a minimum investment of ₹14,868 at the upper price band. Additionally, the company reserved 58,035 shares for its employees, offering them at a discount of ₹54 per share.

Company Profile and Business Operations

Founded in 2004, Corona Remedies has established itself as a key player in the Indian Pharmaceutical Market (IPM). The Ahmedabad-based company focuses on developing, manufacturing, and marketing a diverse portfolio of products across several high-growth therapeutic areas. Its primary segments include women's healthcare, cardiology, pain management, and urology. The company's product portfolio comprises 71 brands catering to various health needs. With a pan-India presence supported by 2,598 medical representatives and two manufacturing facilities in Gujarat, Corona Remedies has built a strong distribution network.

Understanding the Grey Market Premium (GMP)

The Grey Market Premium is an unofficial indicator of investor sentiment before an IPO's listing. It represents the price at which shares are traded in the grey market. For Corona Remedies, the GMP surged to as high as ₹340 per share, or 32% above the issue price. This indicates that investors are willing to pay a significant premium over the offer price, anticipating a strong listing. While GMP is not an official metric, it often provides a directional clue about the potential listing gains.

Analyst Expectations and Market Outlook

Market analysts are optimistic about Corona Remedies' debut, citing the strong subscription figures and robust GMP. Experts like Shivani Nyati of Swastika Investmart Ltd have projected a healthy listing premium of 25% to 27%, with an expected listing price in the range of ₹1,330 to ₹1,350 per share. The company's solid fundamentals, diverse product portfolio, and established presence in key therapeutic segments are considered key strengths. The stock's performance post-listing will be closely watched as it could influence investor sentiment towards future IPOs in the pharmaceutical sector.

Key Financial Metrics

Before the IPO, Corona Remedies demonstrated strong financial health, which likely contributed to the positive investor response. The company's key performance indicators provide insight into its valuation and operational efficiency.

Conclusion and Path Forward

The strong investor demand and high grey market premium for the Corona Remedies IPO point towards a potentially successful listing on December 15th. The company's established market position and consistent financial performance have resonated well with investors. The successful listing would provide a favorable exit for the selling shareholders and offer new investors an opportunity to participate in a growing pharmaceutical company. The market will now await the stock's performance on its trading debut to see if it meets the high expectations set by pre-listing indicators.